Glimsay M2 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The prolonged-release formulation ensures a steady plasma concentration, optimizing therapeutic efficacy while minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glimsay M2 Forte is prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular conditions. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and, rarely, lactic acidosis. Patient education regarding adherence, lifestyle modification, and recognition of hypoglycemia symptoms is crucial for effective diabetes management with Glimsay M2 Forte Tablet PR.